

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Iris PECKER et al.

Serial No.: 09/759,207

Filed: January 16, 2001

For: HEPARANASE SPECIFIC  
MOLECULAR PROBES AND  
THEIR USE IN RESEARCH  
AND MEDICAL APPLICATIONS

Examiner: Amy M. Decloux

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

Group Art Unit: 1644

Attorney  
Docket: 00/21505

RECEIVED

MAY 30 2003

TECH CENTER 1600/2900

RESPONSE TRANSMITTAL

Sir:

- (1) Applicant is a:  
☒ small entity ☐ verified statement attached  
☐ other than small entity ☒ verified statement filed
- (2) The fee for claims 37 CFR 1.16(b)-(d) has been calculated as shown below:

CLAIMS AMENDED		
FOR:	ON FILE	CLAIMS
TOTAL CLAIMS	10	12
INDEP CLAIMS	12	4

SMALL ENTITY	
RATE	FEE
x 9=	\$
1 x 42=	\$ 42
TOTAL	\$ 42

OTHER THAN A SMALL ENTITY	
RATE	FEE
x 18=	\$
x 84=	\$
TOTAL	\$

- (3) An amendment ☒ is filed herewith  
☐ has been filed
- (4) Please charge the claim surcharge fee and any other amount required to Deposit Account No. **50-1407**.  
 A duplicate copy of this form is enclosed.

05/28/2003 BSAYASI1 00000059 501407 09759207  
 02 FC:2201 42.00 CH

Respectfully submitted,

*Sol Sheinbein*  
 Sol Sheinbein  
 Registration No. 25,457

Date: May 27, 2003



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**In re Application of:**

PECKER ET AL.

**Serial No.:** 09/759,207

Filed: 16 January, 2001

**For: HEPARANASE SPECIFIC MOLECULAR PROBES...**

**Examiner: A. M. DECLoux**

Commissioner of Patents and Trademarks  
Washington, D.C. 20231

www.pearsoned.com

**Group Art Unit: 1644**

Attorney  
Docket: 00/21505

RECEIVED

MAY 30 2003

TECH CENTER 1600/2900

## RESPONSE TO OFFICE ACTION

Dear Sir:

In Response to the Office Action sent on November 25, 2002, which is being submitted on or before May 25, 2003, and for which three months' late fees are due and are enclosed herewith, please make the following changes:

**In the Specification:**

**Please amend page 20 as follows:**

**Amended page 20, complete paragraph to be inserted before line one:**

--The present invention also encompasses a polypeptide having heparanase activity, which shares at least 60% homology, preferably at least 70% homology, more preferably at least 80% homology, most preferably at least 90% homology with SEQ ID NO:2. Homology between the polypeptide and SEQ ID NO:2 may be determined with the sequence analysis software package developed by the Genetic Computer Group (GCG) at the University of Wisconsin.--

05/28/2003 BSAYASII 00000059 09759207  
42.00 CH